Inflection Biosciences Announces Pre-clinical Data to be Presented at 2018 AACR Targeting PI3K/mTOR
Dublin, Ireland, November 28th, 2018 – Inflection Biosciences Ltd, a private company developing innovative therapeutics for cancer, today...
Inflection Biosciences Announces Pre-clinical Data to be Presented at 2018 AACR Targeting PI3K/mTOR
Inflection Biosciences Announces Pre-clinical Data on IBL-202 to be Presented at ASH 2018 Meeting
Inflection Biosciences Announces Research Collaboration with MD Anderson Cancer Center.
Inflection Biosciences Announces Publication of Positive Data for Inhibitor Against CLL
Inflection Biosciences and Trinity College Dublin Announce Immuno-Oncology Research Collaboration
Inflection Biosciences Announces Presentation at the 2018 AACR Annual Meeting